David Newble Joins TTP Labtech as New Managing Director
News Jun 18, 2015
TTP Labtech, a world leader in the design and development of automated instrumentation and consumables for life science applications, is pleased to announce the appointment of David Newble as its new managing director. Dr. Jas Sangera, founder, managing director and key driver for the company for the last 14 years, will continue his role as the company’s chairman.
David Newble has a proven track record of growing life sciences companies and bringing new technologies and products to the market and is therefore well placed to lead continued growth at TTP Labtech. He was previously chief executive officer (CEO) at TAP Biosystems (now part of Sartorius Stedim Biotech Group), a leading provider of automated cell culture and fermentation systems. During David’s time as CEO, TAP developed and launched a range of small scale automated bioreactors, growing its cell culture business four-fold as a result.
Over the last 14 years TTP Labtech has grown from The Technology Partnership’s (TTP’s) consultancy business to become a global leader in the field of life science automation and instrumentation. David’s appointment will enable TTP Labtech to further strengthen its market position by launching more products and expanding into new application areas.
Commenting on his appointment, David Newble said, “I am excited to be joining TTP Labtech. There is a strong, expert team and a pipeline of innovative new products. I am looking forward to continuing to work with customers to drive product development and as a result build on the success that TTP Labtech has enjoyed historically.”
Jas Sanghera, outgoing managing director remarked “As one of the founders of TTP 28 years ago and then as a founder of TTP Labtech in 2001, it is of course sad to be leaving. However, I feel David is the perfect person to continue the role of managing director and lead the company into the next stage of its growth and success. I am very proud of our many technical and commercial achievements but I am also proud of the way in which we have always seen people as our greatest asset. I am very pleased to be able to remain involved in the company while having more time to spend pursuing my other interests.”
Synthetic Material That Detects Enzymatic ActivityNews
Scientists integrate protein and polymer building blocks to create stimulus-responsive systemsREAD MORE
Regenerative Medicine Meets Clever Engineering to Accommodate Bone GraftsNews
Personalized bone grafts developed to repair bone defects from disease or injuryREAD MORE
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019